恩南塔製藥公司
US ˙ NasdaqGS ˙ US29251M1062

簡介

本頁面提供了有關 Stefan Fischer 已知的內部交易歷史的全面分析。內部人士包括公司的高管、董事或重要投資者。一般而言，基於內幕、非公開信息進行交易是非法的。這並不意味著他們在自己的公司進行任何交易都是非法的。但是，他們必須透過Form 4向美國證券交易委員會（SEC）報告所有交易。盡管存在這些限制，學術研究表明，內部人士 - 整體而言 - 在自己公司中的投資表現往往優於市場。

平均交易盈利能力

「平均交易盈利能力」衡量了內部人士在過去三年中所有非計劃性的公開市場購買交易的平均回報率。計算過程包括檢查每筆交易，排除了作為10b5-1交易計劃的一部分的交易。然後，對每筆交易在3、6和12個月的表現進行平均，以生成該筆交易最終的表現指標。最終，將所有交易的表現指標進行平均，計算出內部人士的總體平均表現指標。列表僅包含在過去兩年中進行過至少三筆交易的內部人士。

如果內部人士的交易盈利能力顯示為"N/A"，則可能是因為該內部人士在過去三年內沒有進行任何公開市場購買交易，或者他們進行的交易距離現在太近，無法計算出可靠的表現指標。

更新頻率：每日

查看收益最高的的內幕交易者列表。

查看排名最高的內部人士。
報告內部持倉的公司

SEC文件顯示Stefan Fischer已報告在以下公司擁有持倉或進行了交易：

證券 職位 最新報告的持倉
US:ACER / Acer Therapeutics Inc 10% Owner 1,697,709
US:PRTO / Tidal Trust Iii - Rcn Pareto Strategic Allocation Etf 10% Owner 500
US:ENTA / Enanta Pharmaceuticals, Inc. 10% Owner 1,144,932
US:CNCE / Concert Pharmaceuticals Inc 10% Owner 0
US:BLUE / bluebird bio, Inc. 10% Owner 15,152
如何解讀這些圖表

以下圖表顯示了在Stefan Fischer進行的每筆公開市場非計劃交易後證券的股價表現。非計劃交易是指沒有作為10b5-1交易計劃的一部分而進行的交易。股價表現以累積百分比變化的方式繪製。例如，如果一筆內部人士交易是在2019年1月1日進行的，該圖表將顯示該證券的每日百分比變化直至當前日期。如果在此期間股價從10美元漲至15美元，則股價的累積百分比變化將為50%。從10美元漲至20美元的價格變化將為100%，而從10美元跌至5美元的價格變化將為-50%。

最終，我們將評估內部人士的交易與股價的超額回報（正向或負向）之間的相關性，以判斷內部人士是否在交易中利用內部信息獲利。如果內部人士有這樣的行為，我們預期看到（a）購買後的正回報，或者（b）賣出後的負回報。對於情況（a），購買圖表將顯示一系列向上傾斜的曲線，表示每次購買後都有正回報。對於情況（b），賣出圖表將顯示一系列向下傾斜的曲線，表示每次賣出後都有負回報。

然而，僅憑這一點還不足以得出結論。例如，如果公司的股價在多年內呈現非周期性上升，我們會預期所有購買後的圖表都呈現向上傾斜。同樣地，多年來呈現非周期性下降的股價會導致賣出後的圖表也呈現向下傾斜。這兩種情況的圖表都不能表示內部人士在進行內幕交易。

最有力的指標是在公司股價呈極度循環波動的情況下，「購買」圖表顯示正向信號，而「賣出」圖表顯示負向趨勢。這種情況強烈暗示內部人士可能根據內幕信息精確地計時進行交易，以獲得財務優勢。

ENTA / Enanta Pharmaceuticals, Inc.內部人士買入 - 短期收益分析

在這一部分，我們分析了在 ENTA / Enanta Pharmaceuticals, Inc. 中進行的每筆非計劃的公開市場內部人士購買的盈利情況。這種分析有助於了解內部人士是否持續產生異常的回報，以及是否值得跟踪。該分析基於每筆交易後一年的情況，結果僅為理論值。

以下表格顯示了最近的自動交易計劃之外的公開市場購買。

交易日期 證券代碼 內部人士 報告
股數		 Reported
價格		 經調整
股數		 經調整
價格		 成本基礎 達到最高利潤的
天數		 達到最高利潤時的
價格		 最高
淨利 ($)		 最高回報率（%）
2013-03-26 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 132,949 14.0000 132,949 14.0000 1,861,286 359 42.7700 3,824,943 205.50

經調整價格 已按拆股調整。經調整股數 已按拆股調整。

ENTA / Enanta Pharmaceuticals, Inc. Insider Trades
ENTA / Enanta Pharmaceuticals, Inc.內部人士賣出 - 短期虧損分析

在這一部分，我們分析了在 ENTA / Enanta Pharmaceuticals, Inc. 中進行的每筆非計劃的公開市場內部人士賣出所達成的短期虧損規避。如果存在持續的虧損規避模式，可能表明未來的內部人士賣出交易預示著價格的下跌。該分析基於每筆交易後一年的情況，

以下表格顯示了最近的自動交易計劃之外的公開市場購買。

交易日期 證券代碼 內部人士 報告
股數		 Reported
價格		 經調整
股數		 經調整
價格		 成本基礎 達到最低利潤的
天數		 達到最低利潤時的
價格		 避免的
最高損失金額($)		 避免的
最高損失率($)
2014-03-04 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 66,506 38.8155 66,506 38.8155 2,581,464 350 32.9500 -390,090 -15.11
2014-03-04 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 88,877 38.8155 88,877 38.8155 3,449,805
2014-03-04 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 274,880 38.8155 274,880 38.8155 10,669,605
2014-03-03 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 1,402 38.8337 1,402 38.8337 54,445
2014-03-03 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 1,874 38.8337 1,874 38.8337 72,774
2014-03-03 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 5,795 38.8337 5,795 38.8337 225,041
2014-02-26 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 8,283 39.9308 8,283 39.9308 330,747
2014-02-26 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 11,069 39.9308 11,069 39.9308 441,994
2014-02-26 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 34,237 39.9308 34,237 39.9308 1,367,111
2014-02-25 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 27,297 38.9189 27,297 38.9189 1,062,369
2014-02-25 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 36,478 38.9189 36,478 38.9189 1,419,684
2014-02-25 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 112,826 38.9189 112,826 38.9189 4,391,064
2014-02-24 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 8,130 39.5093 8,130 39.5093 321,211
2014-02-24 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 10,865 39.5093 10,865 39.5093 429,269
2014-02-24 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 33,602 39.5093 33,602 39.5093 1,327,591
2014-02-21 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 1,218 40.0000 1,218 40.0000 48,720
2014-02-21 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 1,628 40.0000 1,628 40.0000 65,120
2014-02-21 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 5,034 40.0000 5,034 40.0000 201,360
2014-02-18 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 1,546 40.1853 1,546 40.1853 62,126
2014-02-18 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 2,066 40.1853 2,066 40.1853 83,023
2014-02-18 ENTA TVM V LIFE SCIENCE VENTURES GMBH & CO KG 6,388 40.1853 6,388 40.1853 256,704

經調整價格 已按拆股調整。經調整股數 已按拆股調整。

ENTA / Enanta Pharmaceuticals, Inc. Insider Trades
PRTO / Tidal Trust Iii - Rcn Pareto Strategic Allocation Etf內部人士買入 - 短期收益分析

在這一部分，我們分析了在 ENTA / Enanta Pharmaceuticals, Inc. 中進行的每筆非計劃的公開市場內部人士購買的盈利情況。這種分析有助於了解內部人士是否持續產生異常的回報，以及是否值得跟踪。該分析基於每筆交易後一年的情況，結果僅為理論值。

以下表格顯示了最近的自動交易計劃之外的公開市場購買。

交易日期 證券代碼 內部人士 報告
股數		 Reported
價格		 經調整
股數		 經調整
價格		 成本基礎 達到最高利潤的
天數		 達到最高利潤時的
價格		 最高
淨利 ($)		 最高回報率（%）
2014-10-27 PRTO TVM Life Science Ventures VI GmbH & Co KG 223,410 10.0000 223,410 10.0000 2,234,100 731
2014-10-27 PRTO TVM Life Science Ventures VI GmbH & Co KG 76,590 10.0000 76,590 10.0000 765,900

經調整價格 已按拆股調整。經調整股數 已按拆股調整。

PRTO / Tidal Trust Iii - Rcn Pareto Strategic Allocation Etf Insider Trades
PRTO / Tidal Trust Iii - Rcn Pareto Strategic Allocation Etf內部人士賣出 - 短期虧損分析

在這一部分，我們分析了在 ENTA / Enanta Pharmaceuticals, Inc. 中進行的每筆非計劃的公開市場內部人士賣出所達成的短期虧損規避。如果存在持續的虧損規避模式，可能表明未來的內部人士賣出交易預示著價格的下跌。該分析基於每筆交易後一年的情況，

以下表格顯示了最近的自動交易計劃之外的公開市場購買。

交易日期 證券代碼 內部人士 報告
股數		 Reported
價格		 經調整
股數		 經調整
價格		 成本基礎 達到最低利潤的
天數		 達到最低利潤時的
價格		 避免的
最高損失金額($)		 避免的
最高損失率($)
當前未知該內部人士及證券組合進行過任何未預先計劃的公開市場交易。

經調整價格 已按拆股調整。經調整股數 已按拆股調整。

PRTO / Tidal Trust Iii - Rcn Pareto Strategic Allocation Etf Insider Trades
歷史內部人交易

該表格顯示了由 Stefan Fischer 進行的所有內幕交易的完整列表，這些交易已向美國證券交易委員會（SEC）披露。

呈報日期 交易日期 表格 證券代碼 證券 代碼 10b5-1 股份 剩餘股份 %
變化		 每股
股價		 交易
金額		 剩餘
金額
2018-08-22 2018-08-01 4 ACER Acer Therapeutics Inc.
Common Stock 		P - Purchase 275,000 1,697,709 19.33 18.00 4,950,000 30,558,762
2018-01-12 2017-12-12 4 ACER Acer Therapeutics Inc.
Common Stock 		P - Purchase 250,000 1,422,709 21.32 12.00 3,000,000 17,072,508
2018-01-12 2017-12-12 4 ACER Acer Therapeutics Inc.
Common Stock 		P - Purchase 21,271 248,756 9.35 12.00 255,252 2,985,072
2018-01-12 2017-12-12 4 ACER Acer Therapeutics Inc.
Common Stock 		P - Purchase 62,062 725,844 9.35 12.00 744,744 8,710,128
2017-09-27 2017-09-19 4 ACER Acer Therapeutics Inc.
Common Stock 		J - Other 1,172,709 1,172,709
2017-09-27 2017-09-19 4 ACER Acer Therapeutics Inc.
Common Stock 		J - Other 227,485 227,485
2017-09-27 2017-09-19 4 ACER Acer Therapeutics Inc.
Common Stock 		J - Other 663,782 663,782
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,727,758
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		2,291,461
2017-09-27 3 ACER Acer Therapeutics Inc.
Common Stock 		3,236,685
2017-06-30 2017-06-22 4/A PRTO PROTEON THERAPEUTICS INC
Series A Convertible Preferred Stock 		P - Purchase 372 500 290.62 1,000.00 372,000 500,000
2017-06-26 2017-06-22 4 PRTO PROTEON THERAPEUTICS INC
Series A Convertible Preferred Stock 		P - Purchase 128 500 34.41 1,000.00 128,000 500,000
2017-06-26 2017-06-22 4 PRTO PROTEON THERAPEUTICS INC
Series A Convertible Preferred Stock 		P - Purchase 372 500 290.62 1,000.00 372,000 500,000
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Option (Right to Purchase) 		J - Other -451,276 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Option (Right to Purchase) 		J - Other -1,316,683 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Warrants (Right to Buy) 		X - Other -39,932 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Warrants (Right to Buy) 		X - Other -116,511 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series D Convertible Preferred Stock 		C - Conversion -1,277,663 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series D Convertible Preferred Stock 		C - Conversion -3,727,823 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series C Convertible Preferred Stock 		C - Conversion -799,043 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series C Convertible Preferred Stock 		C - Conversion -2,331,391 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series B Convertible Preferred Stock 		C - Conversion -835,121 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series B Convertible Preferred Stock 		C - Conversion -2,436,618 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series A-1 Convertible Preferred Stock 		C - Conversion -717,260 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series A-1 Convertible Preferred Stock 		C - Conversion -2,092,735 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series A Convertible Preferred Stock 		C - Conversion -1,531,518 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Series A Convertible Preferred Stock 		C - Conversion -4,468,482 0 -100.00
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		X - Other 39,932 1,943,059 2.10 4.60 183,779 8,942,540
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		X - Other 116,511 1,903,127 6.52 4.60 536,219 8,758,761
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		C - Conversion 379,462 1,786,616 26.97
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		C - Conversion 1,107,154 1,407,154 369.05
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		P - Purchase 76,590 300,000 34.28 10.00 765,900 3,000,000
2014-10-30 2014-10-27 4 PRTO PROTEON THERAPEUTICS INC
Common Stock 		P - Purchase 223,410 223,410 10.00 2,234,100 2,234,100
2014-03-07 2014-03-04 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -274,880 1,144,932 -19.36 38.82 -10,669,605 44,441,108
2014-03-07 2014-03-04 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -88,877 370,187 -19.36 38.82 -3,449,805 14,368,993
2014-03-07 2014-03-04 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -66,506 276,999 -19.36 38.82 -2,581,464 10,751,855
2014-03-07 2014-03-03 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -5,795 1,419,812 -0.41 38.83 -225,041 55,136,553
2014-03-07 2014-03-03 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,874 459,064 -0.41 38.83 -72,774 17,827,154
2014-03-07 2014-03-03 4/A ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,402 343,505 -0.41 38.83 -54,445 13,339,570
2014-03-05 2014-03-04 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -274,880 1,178,534 -18.91 38.82 -10,669,605 45,745,386
2014-03-05 2014-03-04 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -88,877 381,052 -18.91 38.82 -3,449,805 14,790,724
2014-03-05 2014-03-04 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -66,506 285,129 -18.91 38.82 -2,581,464 11,067,425
2014-03-05 2014-03-03 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -5,795 1,453,414 -0.40 38.83 -225,041 56,441,443
2014-03-05 2014-03-03 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,874 469,929 -0.40 38.83 -72,774 18,249,082
2014-03-05 2014-03-03 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,402 351,635 -0.40 38.83 -54,445 13,655,288
2014-02-27 2014-02-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -34,237 1,459,209 -2.29 39.93 -1,367,111 58,267,383
2014-02-27 2014-02-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -11,069 471,803 -2.29 39.93 -441,994 18,839,471
2014-02-27 2014-02-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -8,283 353,037 -2.29 39.93 -330,747 14,097,050
2014-02-27 2014-02-25 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -112,826 1,493,446 -7.02 38.92 -4,391,064 58,123,276
2014-02-27 2014-02-25 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -36,478 482,872 -7.02 38.92 -1,419,684 18,792,847
2014-02-27 2014-02-25 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -27,297 361,320 -7.02 38.92 -1,062,369 14,062,177
2014-02-25 2014-02-24 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -33,602 1,572,670 -2.09 39.51 -1,327,591 62,135,091
2014-02-25 2014-02-24 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -10,865 508,485 -2.09 39.51 -429,269 20,089,886
2014-02-25 2014-02-24 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -8,130 380,487 -2.09 39.51 -321,211 15,032,775
2014-02-25 2014-02-21 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -5,034 1,606,272 -0.31 40.00 -201,360 64,250,880
2014-02-25 2014-02-21 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,628 519,350 -0.31 40.00 -65,120 20,774,000
2014-02-25 2014-02-21 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,218 388,617 -0.31 40.00 -48,720 15,544,680
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock 		C - Conversion -288,407 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock 		C - Conversion -1,084,813 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock 		C - Conversion -561,550 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock 		C - Conversion -841,493 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock 		C - Conversion -3,165,187 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock 		C - Conversion -1,638,450 0 -100.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 22,713 378,703 6.38 14.00 317,982 5,301,842
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 66,287 1,104,969 6.38 14.00 928,018 15,469,566
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 51,045 355,990 16.74
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 192,003 304,945 170.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 99,389 112,942 733.34
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 148,936 1,038,682 16.74
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 560,211 889,746 170.00
2014-02-20 2014-02-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		C - Conversion 289,991 329,535 733.34
2014-02-20 2014-02-18 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -6,388 1,611,306 -0.39 40.19 -256,704 64,750,815
2014-02-20 2014-02-18 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -2,066 520,978 -0.39 40.19 -83,023 20,935,657
2014-02-20 2014-02-18 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		S - Sale -1,546 389,835 -0.40 40.19 -62,126 15,665,636
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		92,641
2014-02-12 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock 		66,650
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 15,152 15,152
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series B Warrants 		J - Other -287,400 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 24,393 24,393
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -462,681 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 12,445 12,445
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 12,445 12,445
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -236,062 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -236,062 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 54,760 54,760
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -1,038,674 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 23,232 23,232
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -440,650 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock Warrants 		J - Other 34,849 34,849
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Warrants 		J - Other -660,982 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series D Convertible Preferred Stock 		C - Conversion -3,010,234 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series C Convertible Preferred Stock 		C - Conversion -3,994,248 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series B Convertible Preferred Stock 		C - Conversion -17,749,014 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-2 Convertible Preferred Stock 		C - Conversion -11,835,834 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Series A-1 Convertible Preferred Stock 		C - Conversion -6,169,117 0 -100.00
2013-06-24 2013-06-24 4 BLUE bluebird bio, Inc.
Common Stock 		C - Conversion 2,254,357 2,254,357
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series G-2 Convertible Preferred Stock 		C - Conversion -2,061,246 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series E Convertible Preferred Stock 		C - Conversion -3,296,888 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series E Convertible Preferred Stock 		C - Conversion -563,503 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series D Convertible Preferred Stock 		C - Conversion -500,000 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series D Convertible Preferred Stock 		C - Conversion -1,130,000 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Series C Convertible Preferred Stock 		C - Conversion -1,017,442 0 -100.00
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		P - Purchase 132,949 1,617,694 8.95 14.00 1,861,286 22,647,716
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 478,247 1,484,745 47.52
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 1,006,498 1,006,498
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 172,030 523,044 49.01
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 155,316 391,381 65.79
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 351,014 351,014
2013-03-28 2013-03-26 4 ENTA ENANTA PHARMACEUTICALS INC
Common Stock 		C - Conversion 236,065 236,065
P
非衍生或衍生證券的公開市場或私下買入
S
非衍生或衍生證券的公開市場或私下賣出
A
公司向內部人員授予、獎勵或以其他方式獲取證券（例如股票期權）
C
衍生工具轉換
D
將證券賣出或轉讓回公司
F
使用從公司收到的證券的一部分來支付行使價或稅務負擔。
G
內部人士贈送或接收他人贈送公司股票
K
股權掉期和類似的避險交易
M
行使或轉換從公司獲得的衍生證券（例如期權）
V
內部人士透過Form 4自願報告的一筆交易
J
其他（附有交易描述的腳註）